Orphazyme A/S EBIT

As of the most recent data (June 2024), ORPH shows a EBIT of $-36M. That compares with $-850M in the prior-year period — up 95.7% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ORPH's EBIT is now $-36M (was $-850M) — a 95.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Orphazyme A/S is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. Orphazyme A/S is at $-36M, which is lower that average. That is roughly 100.2% below the sector mean. Use the comparison chart on this page to see how ORPH stacks up against individual peers as well.

Tracking ORPH's ebit over time shows whether Orphazyme A/S is scaling, shrinking, or reshaping that part of the business. The current reading is $-36M That compares with $-850M in the prior-year period — up 95.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Orphazyme A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-36M) with ownership activity and broader fundamentals.